vimarsana.com

Latest Breaking News On - Failure society - Page 1 : vimarsana.com

High Prevalence of Cognitive Impairment in Patients with Heart Failure Shown to Negatively Impact Disease Self-Management

/PRNewswire/ Cognitive impairment is prevalent in patients living with heart failure and was shown to negatively impact functional abilities, life.

United statesEiranz gorodeskiLaura pokoJamesc fangUniversity of utahHeart failure society of america incCase western reserve university school of medicineUniversity hospitals harrington heart vascular instituteHeart failure society of americaHeart failure societyCognitive impairmentHeart failureAmerica scientific statementCardiac failureUniversity hospitals harrington heartVascular institute

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

Commercial launch of INPEFA® continues to progress. with increasing demand across the cardiology community and improving payer access Patient enrollment underway in PROGRESS, a Phase 2b study of.

United statesSan diegoLisa defrancescoMichaelj daviesCraig granowitzAlina cocuzzaDiabetic neuropathy study group neurodiabLexicon pharmaceuticals incDevelopment rd expensesAmerican heart association scientific sessionsCompany toHeart failure society of americaGlobenewswire incEuropean association for the study of diabetesLexicon pharmaceuticalsExchange commission

Novel Nerve Ablation Procedure Explored for HFpEF

Splanchnic nerve ablation for volume management passes a feasibility hurdle

United statesNorth carolinaKavita sharmaFudimm endovascularDuke university health in durhamHeart failure society of americaJohns hopkins university in baltimoreMarat fudimDuke university healthHeart failure societyJohns hopkins universityFailure society

Cardiol Therapeutics : MATERIAL CHANGE REPORT - Form 6-K -October 11, 2023 at 10:03 am EDT

MATERIAL CHANGE REPORT - Name and Address of Company Cardiol Therapeutics Inc. 2265 Upper Middle Road East, Suite 602 Oakville, Ontario,.

United statesNuevo leóxChris waddickAndrew hamerCardiol therapeutics incDrug administrationCompany annual report on formAmerican heart associationAmerican college of cardiologyNational instrumentHead of research developmentMiddle road eastElectronic document analysisNews releaseSubcutaneously administered cannabidiolHeart failure

Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting

TN-301 Demonstrates Tolerability, Potential for Once Daily Dosing, Target Engagement and Selectivity for HDAC6 in Phase 1 Clinical Trial of Healthy Participants

United statesWhit tingleyTenaya therapeutics incAdministration of inhibitorsHeart failure society of americaTenaya therapeuticsFailure societyAnnual scientificChief medicalDemonstrate safetyTarget engagementOnce daily dosinHighly selectiveShows target engagementBenefit observedAdditive improvements

vimarsana © 2020. All Rights Reserved.